Eli Lilly and Company (LLY) Expected to Post Earnings of $1.03 Per Share
Wall Street brokerages expect Eli Lilly and Company (NYSE:LLY) to report earnings of $1.03 per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Eli Lilly and’s earnings, with the lowest EPS estimate coming in at $0.98 and the highest estimate coming in at $1.06. Eli Lilly and posted earnings of $0.86 per share in the same quarter last year, which indicates a positive year over year growth rate of 19.8%. The company is scheduled to announce its next quarterly earnings report before the market opens on Tuesday, July 25th.
According to Zacks, analysts expect that Eli Lilly and will report full year earnings of $4.12 per share for the current financial year, with EPS estimates ranging from $4.08 to $4.15. For the next financial year, analysts forecast that the firm will report earnings of $4.42 per share, with EPS estimates ranging from $4.29 to $4.66. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Eli Lilly and.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.96 by $0.02. Eli Lilly and had a return on equity of 26.64% and a net margin of 10.13%. The business had revenue of $5.23 billion for the quarter, compared to analyst estimates of $5.22 billion. During the same quarter in the previous year, the firm earned $0.83 earnings per share. The company’s revenue was up 7.5% on a year-over-year basis.
LLY has been the topic of a number of research reports. BMO Capital Markets set a $71.00 price target on Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, April 25th. Credit Suisse Group restated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, March 21st. Barclays PLC raised their price target on Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, April 7th. Zacks Investment Research downgraded Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, June 27th. Finally, Jefferies Group LLC restated a “buy” rating and set a $92.00 price target (down previously from $94.00) on shares of Eli Lilly and in a research note on Saturday, April 29th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company. Eli Lilly and currently has an average rating of “Buy” and a consensus target price of $87.75.
COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/07/18/eli-lilly-and-company-lly-expected-to-post-earnings-of-1-03-per-share.html.
Shares of Eli Lilly and (NYSE:LLY) traded up 0.07% during midday trading on Tuesday, hitting $83.70. The stock had a trading volume of 1,704,532 shares. Eli Lilly and has a one year low of $64.18 and a one year high of $86.72. The firm has a 50 day moving average price of $81.98 and a 200 day moving average price of $81.02. The stock has a market cap of $88.41 billion, a PE ratio of 40.47 and a beta of 0.35.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.49%. Eli Lilly and’s dividend payout ratio is currently 100.48%.
In related news, SVP Enrique A. Conterno sold 25,000 shares of Eli Lilly and stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the completion of the transaction, the senior vice president now directly owns 114,217 shares of the company’s stock, valued at $9,452,598.92. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 474,733 shares of company stock valued at $39,634,487. 0.20% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. Ronna Sue Cohen boosted its position in shares of Eli Lilly and by 0.4% in the second quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after buying an additional 9 shares in the last quarter. Sunbelt Securities Inc. boosted its position in shares of Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock valued at $313,000 after buying an additional 17 shares in the last quarter. Northwest Quadrant Wealth Management LLC boosted its position in shares of Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after buying an additional 19 shares in the last quarter. Pillar Pacific Capital Management LLC boosted its position in shares of Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock valued at $595,000 after buying an additional 20 shares in the last quarter. Finally, Guardian Life Insurance Co. of America boosted its position in shares of Eli Lilly and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 3,747 shares of the company’s stock valued at $315,000 after buying an additional 25 shares in the last quarter. 75.47% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.